Perfluorohexyloctane Eyedrops for Meibomian Gland Disease April 2023

Perfluorohexyloctane, a preservative-free lipophilic compound, which has bee marketed in Europe as an eyedrop for dry eve disease (DED)for years has been shown to improve symptoms of burning, foreign body sensation, and blurry vision. Tian et al. In the journal JAMA, ophthalmology, April 2023, evaluated the compound's efficacy and safety in Chinese patients who had DED associated with meibomian gland disease (MGD) They found that the perfluorhexyloc-tane eyedrops quickly relieved the signs and symptoms of MGD-associated dry eye disease. Though they were safe and well-tolerated, they did not show any significant changes in meibomian, and Gland dysfunction, to your break up time, or Schirmers, one outcomes.

this was a phase 3 double mask clinical trial involving 312 patients in 15 hospitals in China. This medication is still not FDA approved for use in the United States